Skip to main content
. 2020 Apr 23;20(1):67–74. doi: 10.3892/ol.2020.11568

Figure 6.

Figure 6.

USP17 suppression decreases PI3K/AKT pathway activation and the viability of non-small cell lung cancer cells. Western blot analysis of p-PI3K, PI3K, p-AKT and AKT protein levels in (A-C) A549 and (D-F) H1299 cells with or without USP17 KD. (G) Cell Counting Kit-8 assay in USP17 KD and NC (G) A549 and (H) H1299 cells treated with cisplatin. ***P<0.001 vs. KD. USP, ubiquitin-specific peptidase; KD, knockdown; NC, negative control; immunoblot; p-, phosphorylated.